R&D Collaboration
Partnering structure :
-
Strategic equity investment
-
Onward is the majority shareholder
Onward works in collaboration with Emercell who have developed generic cell immunotherapy platform (OT-C001) derived from Natural Killer (NK) cells, designed for synergistic combination with antibodies.
Emercell is a biopharmaceutical company operating from Paris and Montpellier, France
Partnering structure :
-
Exclusive worldwide license and co-development agreement (OT-A201)
-
Strategic equity investment
BIOMUNEX Pharmaceuticals is a biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. In particular, BIOMUNEX is developing a disruptive biological approach, the so-called BiXAb-MAIT engagers, that redirect MAIT cells to kill cancer cells, and can become a true game changer in the treatment of cancer patients.
Onward Therapeutic has entered into an exclusive collaboration, worldwide option and license agreement with ICM based on a research program in onco-metabolism (OT-S00X).
Created in 1923, the ICM is one of the 18 French Cancer Control Centers (CLCC), members of Unicancer, the only French hospital network dedicated 100% to the fight against cancer.
Its mission is to care for local and regional patients, and offer them innovative scientific, technological, and organizational care, particularly for breast cancer, digestive cancers, gynaecological cancers, prostate cancer, sarcomas, and more.